Clinical Research Directory

Inclusion Criteria: * Age18 - 79 years old * Diagnosed with any type of lymphoma \[Hodgkin, non-Hodgkin (B- or T-cell)\] and planned for BEAM-AHCT * KPS \> 70 * Cardiac ejection fraction of \> 45% * Hemoglobin-adjusted diffusing capacity of carbon monoxide (DLCO) of ≥45% * Creatinine clearance of ≥ 40 mL/min * Completion of most recent systemic therapy within 12 weeks of enrollment * Complete or partial response to systemic chemotherapy by IWG Working Group Criteria. * Total bilirubin \< 2.0 mg/dL in the absence of suspected Gilbert's disease (if Gilbert's disease is suspected, the total bilirubin must be ≤3.0 mg/dL), and AST \& ALT \< 2.5 ULN. * Minimum stem cell dose of 2 x 10\*6 CD34+ cells/kg Exclusion Criteria: * Disease progression by IWG Working Group since last therapy * Pregnant or lactating females * Contraindication to CE melphalan or any of the required supportive treatments, including hypersensitivity to G-CSF or pegfilgrastim * Any known allergy or allergic reactions to Captisol * Any other medical condition or laboratory evaluation that, in the treating physician's or principal investigator's opinion, makes the patient unsuitable to participate in this clinical trial